Lineage Cell Therapeutics (LCTX) EPS (Basic) (2016 - 2025)
Historic EPS (Basic) for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$0.13.
- Lineage Cell Therapeutics' EPS (Basic) fell 55000.0% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 14166.67%. This contributed to the annual value of -$0.09 for FY2024, which is 2264.96% up from last year.
- Latest data reveals that Lineage Cell Therapeutics reported EPS (Basic) of -$0.13 as of Q3 2025, which was down 55000.0% from -$0.13 recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' EPS (Basic) registered a high of -$0.01 during Q1 2021, and its lowest value of -$0.17 during Q4 2021.
- In the last 5 years, Lineage Cell Therapeutics' EPS (Basic) had a median value of -$0.03 in 2021 and averaged -$0.05.
- Data for Lineage Cell Therapeutics' EPS (Basic) shows a peak YoY increase of 8333.33% (in 2021) and a maximum YoY decrease of 180000.0% (in 2021) over the last 5 years.
- Lineage Cell Therapeutics' EPS (Basic) (Quarter) stood at -$0.17 in 2021, then surged by 82.35% to -$0.03 in 2022, then grew by 8.99% to -$0.03 in 2023, then surged by 40.54% to -$0.02 in 2024, then plummeted by 700.77% to -$0.13 in 2025.
- Its last three reported values are -$0.13 in Q3 2025, -$0.13 for Q2 2025, and -$0.02 during Q1 2025.